Compounds with a combination of cannabinoid CB1 antagonism and serotonin reuptake inhibition

A pharmaceutical composition comprising, at least one pharmaceutically acceptable carrier and/or at least one pharmaceutically acceptable auxiliary substance, a pharmacologically active amount of at least one compound of formula (1):

• or a tautomer, stereoisomer, N-oxide, or a pharmacologically acceptable salt of any of the foregoing, wherein:
• A is (A2):
• wherein the wavy bond is the point at which the fragment is attached to moiety N (wherein N represents a non-basic nitrogen atom) in formula (1), R1 and R2 independently are chosen from a hydrogen atom, a trifluoromethyl group, and a halogen atom, R4 is chosen from a hydrogen atom, a halogen atom, methyl, ethyl, trifluoromethyl, hydroxymethyl, fluoromethyl, 2,2,2-trifluoroethyl, propyl, methylsulfanyl, methylsulfinyl, methylsulfonyl, ethylsulfanyl, ethylsulfinyl, ethylsulfonyl, C1-3-dialkyl -aminomethyl, pyrrolidin-1-ylmethyl, piperidin-1-ylmethyl, and morpholin-4-ylmethyl group, and
• the NRTB sequence of formula (1) is chosen from one of the fragments (NRTB1), (NRTB2), (NRTB3), (NRTB5), (NRTB6), (NRTB7), (NRTB8), (NRTB9), and (NRTB10):
• wherein R is chosen from a hydrogen atom and a (C1-C3)-alkyl group.